Product Description
Treatment with Rocaltrol plus Caltrate D or Caltrate D for 12 months in elderly Chinese postmenopausal women effectively increased BMD at the lumbar spine. Rocaltrol plus Caltrate D was more effective at the lumbar spine than Caltrate D alone. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19262561/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Chile | Colombia | Czech | Denmark | Finland | Hungary | Ireland | Slovakia | Sweden | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Vitamin D Deficiency|Osteoporosis
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2200066020 | N/A |
Not yet recruiting |
Osteoporosis |
2023-10-25 |
|
| ZZ13-YQ-039 | N/A |
Unknown status |
Osteoporosis |
2022-12-01 |
|
| ChiCTR-IPR-15007081 | N/A |
Completed |
Bone Cancer|Breast Cancer |
2016-03-06 |
|
| 2014-005619-18 | P4 |
Completed |
Vitamin D Deficiency|Osteoporosis |
2015-08-21 |